Chemistry of DNA-binding Molecules

Abstract

DNA-binding molecules regulate gene expression, replication, repair, and transcription, making their research crucial to molecular biology. This review investigated their architectures, processes, and impacts on cancer research and therapy to determine their biological and therapeutic potential. A thorough examination of published data on DNA-binding agents, including intercalators, groove binders, and metal complexes, focused on their chemical properties, biological activity, and therapeutic significance. Doxorubicin intercalated between base pairs to inhibit replication and transcription, whereas cisplatin produced covalent cross-links with guanine bases to cause tumor cell death. Multiple derivatives of metal complexes reduced tumor development by over 70% in leukemia models as DNA probes and therapeutics. Also reviewed, Dps proteins in *Escherichia coli* showed that their non-specific DNA binding offered up to 65% oxidative stress resistance compared to control cultures, validating DNA-protein protection as a survival strategy. In Phase II studies, amsacrine caused substantial remission in acute leukemia patients, whereas doxorubicin was more effective across many cancer types but had greater cardiotoxicity concerns. Selectivity, toxicity, and resistance limit DNA-targeting medicines, although they are successful. Chemical modifications like hydrophobic tailoring and sequence-specific binding have enhanced binding affinity and therapeutic index, yet only 10% of candidate compounds get clinical approval. Recent studies show that AI-driven design has expedited screening, lowering development costs by 30% and durations by 3–5 years. These data suggest that DNA-binding medicines have great potential in cancer, but safer, more selective, and resistance-free therapy are still needed.